IGM Biosciences, Inc.

NasdaqGS IGMS

IGM Biosciences, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2024: USD -6.44 M

IGM Biosciences, Inc. Capital Expenditure is USD -6.44 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 52.76% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

IGM Biosciences, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -13.63 M, a -46.95% change year over year.
IGM Biosciences, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -9.27 M, a 49.01% change year over year.
IGM Biosciences, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -18.19 M, a -59.64% change year over year.
IGM Biosciences, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -11.39 M, a -444.13% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqGS: IGMS

IGM Biosciences, Inc.

CEO	Ms. Mary Beth Harler M.D.
IPO Date	Sept. 18, 2019
Location	United States
Headquarters	325 East Middlefield Road
Employees	198
Sector	Healthcare
Industries Biotechnology Pharmaceuticals Vaccines

Description

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Key trends

Past 5 years